San Francisco-based pharmaceutical company Jaguar Health specializes in developing and commercializing innovative gastrointestinal pharmaceuticals derived from plants commonly found in rainforest zones. Collaborating with indigenous populations, Jaguar Health harnesses the power of natural substances to create groundbreaking medicinal products. Their flagship product, Mytesi, is a botanical drug containing crofelemer and is specifically designed to provide relief from noninfectious diarrhea for patients living with HIV/AIDS and undergoing antiretroviral therapy.
Through extensive research, Jaguar Health discovered the remarkable potential of crofelemer as a key ingredient in certain plants for alleviating various pathological conditions. Today, the company prioritizes organic and sustainable cultivation methods, adhering to Fair Trade Certified conditions during the harvesting and exportation of their products.
Notably, Mytesi stands out as the sole FDA-approved oral drug that follows FDA botanical guidance in its processing. So, how did the company overcome commercialization hurdles, such as allocating funding, recruiting employees, and identifying expert advisors? In this article, Jaguar Health's founder and CEO Lisa Conte shares insights on building a successful life sciences organization through innovation.